Literature DB >> 9307247

Calcium channels in neurological disease.

D A Greenberg1.   

Abstract

Channels involved in the influx and intracellular mobilization of calcium have been implicated as targets of diverse genetic and immune-mediated neurological diseases. These include the L-type voltage-gated calcium channel of skeletal muscle (hypokalemic periodic paralysis), the neuronal P/Q-type voltage-gated calcium channel (familial hemiplegic migraine, episodic ataxia type 2, spinocerebellar ataxia 6, and Lambert-Eaton myasthenic syndrome), and the skeletal muscle ryanodine receptor (malignant hyperthermia and central core disease). The discovery of these and other calcium channelopathies should help to clarify how different mutations affect channel function and how altered channel function produces disease, and may lead to new treatments for these conditions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9307247     DOI: 10.1002/ana.410420302

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  10 in total

Review 1.  Ion channels and neurology.

Authors:  S M Zuberi; M G Hanna
Journal:  Arch Dis Child       Date:  2001-03       Impact factor: 3.791

Review 2.  Ion channel genes and human neurological disease: recent progress, prospects, and challenges.

Authors:  E C Cooper; L Y Jan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

3.  Omega-conotoxin MVIIC attenuates neuronal apoptosis in vitro and improves significant recovery after spinal cord injury in vivo in rats.

Authors:  Karen M Oliveira; Mário Sérgio L Lavor; Carla Maria O Silva; Fabíola B Fukushima; Isabel R Rosado; Juneo F Silva; Bernardo C Martins; Laís B Guimarães; Marcus Vinícius Gomez; Marília M Melo; Eliane G Melo
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 4.  Can calcium antagonists provide a neuroprotective effect in Parkinson's disease?

Authors:  R L Rodnitzky
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

5.  A novel syndrome of episodic muscle weakness maps to xp22.3.

Authors:  M M Ryan; P Taylor; J A Donald; R A Ouvrier; G Morgan; G Danta; M F Buckley; K N North
Journal:  Am J Hum Genet       Date:  1999-10       Impact factor: 11.025

6.  Episodic ataxia mutations in Kv1.1 alter potassium channel function by dominant negative effects or haploinsufficiency.

Authors:  P Zerr; J P Adelman; J Maylie
Journal:  J Neurosci       Date:  1998-04-15       Impact factor: 6.167

7.  Paroxysmal dyskinesias in the lethargic mouse mutant.

Authors:  Zubair Khan; H A Jinnah
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

8.  Lambert-Eaton myasthenic syndrome as a cause of persistent neuromuscular weakness after a mediastinoscopic biopsy -A case report-.

Authors:  Cheol Jin Lee; Se Hun Lim; Chee Mahn Shin; Young Jae Kim; Young Kyun Choe; Soon Ho Cheong; Kun Moo Lee; Jeong Han Lee; Young Hwan Kim; Kwang Rae Cho; Sang Eun Lee; Jong Suk Bae
Journal:  Korean J Anesthesiol       Date:  2010-07-21

Review 9.  Migraine prevention trials and optimized acute therapy: translating lessons learned into clinical practice.

Authors:  Abouch Valenty Krymchantowski; Carla da Cunha Jevoux
Journal:  Curr Pain Headache Rep       Date:  2008-06

10.  Conotoxin MVIIA improves cell viability and antioxidant system after spinal cord injury in rats.

Authors:  Karen M Oliveira; Nancy S Binda; Mário Sérgio L Lavor; Carla M O Silva; Isabel R Rosado; Endrigo L A Gabellini; Juliana F Da Silva; Camila M Oliveira; Marília M Melo; Marcus Vinícius Gomez; Eliane G Melo
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.